Constellation Pharma teams up with Genentech


Constellation Pharmaceuticals Inc. said that it has entered into a major strategic agreement with Genentech, a California-based member of the Roche Group, to launch a broad collaboration based on the science of epigenetics and chromatin biology to discover and develop treatments for cancer and other serious diseases.

Under the agreement, Cambridge-based Constellation said it will receive committed funding of $95 million, comprising of an upfront payment and research funding for a three-year period. Constellation said it will be eligible for development and commercialization milestone payments as well as up to double-digit royalties on commercial sales of multiple products by Genentech.

Constellation’s press release also noted that Genentech has a future option to acquire all outstanding shares of Constellation based on pre-negotiated terms, which include a significant initial acquisition payment plus contingent value rights payments based on the future successful development and commercialization of multiple products by Genentech.

Chris Reidy can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.